Benign Prostatic Hyperplasia (BPH)

Understand

Overview

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland, resulting from growth of epithelial and stromal cells in the so-called transition zone of the prostate, which surrounds the urethra. The enlarged tissue compresses the urethra and bladder neck, producing a set of symptoms known as lower urinary tract symptoms (LUTS) — a weakened urine stream, more frequent urination, nocturia (nighttime urination), a feeling of incomplete bladder emptying, and sudden urinary urgency. BPH is one of the most common urological conditions of middle and older age — a meta-analysis pooling data from 25 countries estimated its lifetime prevalence at around 26%.

The prevalence of BPH rises markedly with age: moderate or severe symptoms affect a far smaller share of men in their 40s than in their 70s, making age the single strongest risk factor for the condition. Additional risk factors include obesity and metabolic syndrome, a sedentary lifestyle, and family predisposition, though the hormonal mechanism (prostate tissue sensitivity to dihydrotestosterone) remains the common denominator regardless of when symptoms first appear.

Diagnosis rests on a history taken with the IPSS (International Prostate Symptom Score) questionnaire, a digital rectal exam assessing gland size and consistency, a PSA test, and, when needed, uroflowmetry (measuring urine flow rate) and ultrasound assessment of post-void residual urine. PSA is a frequent source of confusion in the context of BPH — the gland enlargement itself, regardless of whether cancer is present, raises PSA levels, so a single elevated result in a man with BPH symptoms is not automatic proof of prostate cancer, only a signal for further, careful evaluation.

One of the most important points to understand is that BPH and prostate cancer are two distinct pathological processes. BPH develops almost exclusively in the transition zone of the gland, while the vast majority of prostate cancers arise in the peripheral zone. There is no solid evidence that benign prostatic hyperplasia itself causally raises the risk of developing prostate cancer — both conditions simply become more common with age and can coexist in the same man independently of one another. This distinction matters practically: a BPH diagnosis should not be treated as a warning sign for cancer, but it also doesn't exempt a man from routine, individually determined prostate cancer risk assessment with his doctor.

For a typical patient, BPH develops gradually, over years, and most often first announces itself through worsened sleep quality from nocturia and growing daytime urinary frequency. Many men delay seeing a doctor, treating these symptoms as an inevitable part of aging, even though effective conservative and pharmacological treatment is widely available even at an early stage.

Who might genuinely benefit from this knowledge? Primarily men over 50 noticing changes in urination, as well as those with risk factors such as obesity or metabolic syndrome, in whom symptoms may appear earlier. This diagnosis is also worth flagging for men considering testosterone therapy, since prostate and PSA evaluation is a standard part of qualifying for such treatment.

BPH remains a chronic, usually slowly progressive condition, but with appropriate treatment and regular monitoring, the vast majority of men maintain good quality of life without needing surgical treatment. The key is reporting symptoms to a doctor early, rather than attempting self-treatment with supplements alone or ignoring worsening symptoms, which if neglected can lead to real complications, including acute urinary retention.